Fierce Pharma July 8, 2024
As the process surrounding Medicare’s drug price negotiations rolls on this summer—and as the pharmaceutical industry continues to loudly voice its complaints—another lawsuit contesting the legal viability of the setup has come up short.
Boehringer Ingelheim’s lawsuit challenging the constitutionality of the Inflation Reduction Act’s (IRA’s) Medicare price negotiations was turned away in the U.S. District Court for the District of Connecticut, according to a July 3 opinion by the court.
In its case, BI had alleged that the IRA violates several parts of the U.S. Constitution, including the First Amendment, plus that the Centers for Medicare & Medicaid Services (CMS) didn’t fulfill legal requirements with its implementation of the law.
After reviewing arguments from both sides, Chief District Judge...
Today's Sponsors
Today's Sponsor